Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA-4948 Monotherapy in Relapsed/Refractory AML or High-Risk MDS
2024-513313-13-00Phase 2Completed
- Sponsor
- Curis, Inc.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of emavusertib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Curis, Inc. Primary endpoints: Phase 1 Safety and Phase 2a Clinical Response in AML and hrMDS (Primary). Started Sep 2024; status: completed.
02
Drugs
emavusertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-513313-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513313-13-00.